-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Neutral on Adient, Lowers Price Target to $13

Benzinga·04/10/2025 18:03:29
Listen to the news
UBS analyst Joseph Spak maintains Adient (NYSE:ADNT) with a Neutral and lowers the price target from $20 to $13.